PubMed:8720080
Annnotations
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-131 | Sentence | denotes | Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. |
| TextSentencer_T2 | 132-381 | Sentence | denotes | CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgG antibody used in the therapy of lymphoma, leukaemia and rheumatoid arthritis, has been expressed in Chinese hamster ovary, Y0 myeloma and NS0 myeloma cell lines. |
| TextSentencer_T3 | 382-496 | Sentence | denotes | These engineered cell lines were grown under different culture conditions, and the antibody isolated and purified. |
| TextSentencer_T4 | 497-775 | Sentence | denotes | N-Linked oligosaccharides, on the CH2 heavy chain region of the antibody, were isolated and analysed by hydrazinolysis, high-performance anion-exchange chromatography with pulsed amperometric detection, laser-desorption mass spectrometry and sequential exoglycosidase treatment. |
| TextSentencer_T5 | 776-981 | Sentence | denotes | Both the glycosylation pattern and the biological activity of CAMPATH-1H, as measured by antibody-dependent cell-mediated cytotoxicity, were markedly affected by the cell line used to express the antibody. |
| TextSentencer_T6 | 982-1085 | Sentence | denotes | It is concluded that glycosylation of the antibody may be important in the clinical outcome of therapy. |
| T1 | 0-131 | Sentence | denotes | Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. |
| T2 | 132-381 | Sentence | denotes | CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgG antibody used in the therapy of lymphoma, leukaemia and rheumatoid arthritis, has been expressed in Chinese hamster ovary, Y0 myeloma and NS0 myeloma cell lines. |
| T3 | 382-496 | Sentence | denotes | These engineered cell lines were grown under different culture conditions, and the antibody isolated and purified. |
| T4 | 497-775 | Sentence | denotes | N-Linked oligosaccharides, on the CH2 heavy chain region of the antibody, were isolated and analysed by hydrazinolysis, high-performance anion-exchange chromatography with pulsed amperometric detection, laser-desorption mass spectrometry and sequential exoglycosidase treatment. |
| T5 | 776-981 | Sentence | denotes | Both the glycosylation pattern and the biological activity of CAMPATH-1H, as measured by antibody-dependent cell-mediated cytotoxicity, were markedly affected by the cell line used to express the antibody. |
| T6 | 982-1085 | Sentence | denotes | It is concluded that glycosylation of the antibody may be important in the clinical outcome of therapy. |
| T1 | 0-131 | Sentence | denotes | Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. |
| T2 | 132-381 | Sentence | denotes | CAMPATH-1H (where CAMPATH is a trade mark of Wellcome group companies), a humanized IgG antibody used in the therapy of lymphoma, leukaemia and rheumatoid arthritis, has been expressed in Chinese hamster ovary, Y0 myeloma and NS0 myeloma cell lines. |
| T3 | 382-496 | Sentence | denotes | These engineered cell lines were grown under different culture conditions, and the antibody isolated and purified. |
| T4 | 497-775 | Sentence | denotes | N-Linked oligosaccharides, on the CH2 heavy chain region of the antibody, were isolated and analysed by hydrazinolysis, high-performance anion-exchange chromatography with pulsed amperometric detection, laser-desorption mass spectrometry and sequential exoglycosidase treatment. |
| T5 | 776-981 | Sentence | denotes | Both the glycosylation pattern and the biological activity of CAMPATH-1H, as measured by antibody-dependent cell-mediated cytotoxicity, were markedly affected by the cell line used to express the antibody. |
| T6 | 982-1085 | Sentence | denotes | It is concluded that glycosylation of the antibody may be important in the clinical outcome of therapy. |
ICD10
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 262-271 | http://purl.bioontology.org/ontology/ICD10/C95.9 | denotes | leukaemia |
| T2 | 276-296 | http://purl.bioontology.org/ontology/ICD10/M06.9 | denotes | rheumatoid arthritis |
| T3 | 287-296 | http://purl.bioontology.org/ontology/ICD10/M13.9 | denotes | arthritis |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 216-219 | FMAID:167179 | denotes | IgG |
| _T2 | 220-228 | FMAID:167180 | denotes | antibody |
| _T3 | 336-341 | FMAID:7209 | denotes | ovary |
| _T4 | 336-341 | FMAID:93687 | denotes | ovary |
| _T5 | 465-473 | FMAID:167180 | denotes | antibody |
| _T6 | 506-522 | FMAID:82742 | denotes | oligosaccharides |
| _T7 | 506-522 | FMAID:196731 | denotes | oligosaccharides |
| _T8 | 561-569 | FMAID:167180 | denotes | antibody |
| _T9 | 865-873 | FMAID:167180 | denotes | antibody |
| _T10 | 972-980 | FMAID:167180 | denotes | antibody |
| _T11 | 1024-1032 | FMAID:167180 | denotes | antibody |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 186-191 | http://purl.bioontology.org/ontology/STY/T096 | denotes | group |
| T2 | 276-286 | http://purl.bioontology.org/ontology/NCBITAXON/572355 | denotes | rheumatoid |
| T3 | 700-705 | http://purl.bioontology.org/ontology/NCBITAXON/62990 | denotes | laser |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-13 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | Glycosylation |
| T2 | 785-798 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T3 | 1003-1016 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T4 | 640-648 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
| T5 | 884-910 | http://purl.obolibrary.org/obo/GO_0001909 | denotes | cell-mediated cytotoxicity |
| T6 | 884-910 | http://purl.obolibrary.org/obo/GO_0001913 | denotes | cell-mediated cytotoxicity |
| T7 | 884-910 | http://purl.obolibrary.org/obo/GO_0042267 | denotes | cell-mediated cytotoxicity |
| T8 | 884-910 | http://purl.obolibrary.org/obo/GO_0090634 | denotes | cell-mediated cytotoxicity |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 220-228 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
| T2 | 465-473 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
| T3 | 561-569 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
| T4 | 865-873 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
| T5 | 972-980 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
| T6 | 1024-1032 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | antibody |
GO-CC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 75-79 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T2 | 370-374 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T3 | 399-403 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T4 | 884-888 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T5 | 942-946 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T6 | 216-228 | http://purl.obolibrary.org/obo/GO_0071736 | denotes | IgG antibody |
EDAM-topics
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 206-215 | http://edamontology.org/topic_2815 | denotes | humanized |
| T2 | 717-734 | http://edamontology.org/topic_3520 | denotes | mass spectrometry |
| T3 | 717-734 | http://edamontology.org/topic_0134 | denotes | mass spectrometry |
EDAM-DFO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 75-89 | http://edamontology.org/data_0963 | denotes | cell lines and |
| T2 | 689-698 | http://edamontology.org/operation_2423 | denotes | detection |
| T3 | 717-734 | http://edamontology.org/data_3147 | denotes | mass spectrometry |
| T4 | 717-734 | http://edamontology.org/data_2536 | denotes | mass spectrometry |
| T5 | 853-861 | http://edamontology.org/data_3108 | denotes | measured |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 252-260 | Disease | denotes | lymphoma | http://purl.obolibrary.org/obo/MONDO_0005062 |
| T2 | 276-296 | Disease | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/MONDO_0008383 |
| T3 | 346-353 | Disease | denotes | myeloma | http://purl.obolibrary.org/obo/MONDO_0005170|http://purl.obolibrary.org/obo/MONDO_0009693 |
| T5 | 362-369 | Disease | denotes | myeloma | http://purl.obolibrary.org/obo/MONDO_0005170|http://purl.obolibrary.org/obo/MONDO_0009693 |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 320-335 | OrganismTaxon | denotes | Chinese hamster | 10029 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 336-341 | Body_part | denotes | ovary | http://purl.obolibrary.org/obo/UBERON_0000992 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 252-260 | Phenotype | denotes | lymphoma | HP:0002665 |
| T2 | 262-271 | Phenotype | denotes | leukaemia | HP:0001909 |
| T3 | 276-296 | Phenotype | denotes | rheumatoid arthritis | HP:0001370 |